Please assess the completion status of the following clinical trial:

Trial Title: RELieving Increasing oEdema Due to Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~A. For the Screening Log (no follow-up envisaged nor linkage to electronic medical records)~1. ≥18 years~2. Heart failure in the investigators opinion (new onset or decompensated chronic heart failure)~3. Planned to receive\>80mg/day of furosemide or equivalent (IV, SC or oral) in the next 24 hours.~4. Worsening symptoms \& signs of congestion in the prior 10 days requiring at least one of the following:~   1. hospitalisation~  2. administration of intravenous diuretics~  3. an increase in the dose of loop diuretic by at least 40mg/day of furosemide (or equivalent) to a total of at least 80mg/day of furosemide (or equivalent)~  4. addition of a thiazide diuretic to treatment with a loop diuretic~B. For the Consented Registry (with linkage to electronic medical records)~1. Fulfils the criteria for the screening log~2. Able and willing to provide written informed consent for registry participation~C. For Randomised Trial Run-in~1. Fulfils criteria for the consented registry~2. Clinical diagnosis of heart failure for at least 4 weeks~3. Congestion as shown by at least one of the following:~   1. Peripheral oedema~  2. Raised venous pressure~  3. Inferior vena cava diameter \>20mm~4. Cardiac dysfunction documented by at least one of the following in the previous three years:~   1. A LVEF\<50%or a report of moderate or severe left ventricular dysfunction~  2. Left atrial diameter \>3.0cm/m2 (body surface area)~  3. Elevated BNP or NT-proBNP (BNP \>150ng/L if in sinus rhythm or \>450ng/L if not in sinus rhythm; NT-proBNP \>500ng/L if in sinus rhythm and \>1500ng/L if not in sinus rhythm)~5. Able and willing to provide written informed consent for the randomised trial~D. For Randomisation~1. Serum potassium \>5.0mmol/L~   * Patients with a serum potassium \>5.0mmol/L may be randomised immediately unless they have severe hyperkalaemia requiring, in the investigators opinion, intravenous treatment or a potassium binding agent.~  * Severe hyperkalaemia should be managed according to the UK Renal Association guidelines of 2014 (https://renal.org/wp-content/uploads/2017/06/hyperkalaemia-guideline-1.pdf). Participants may be reconsidered for the trial once such interventions are no longer considered necessary.~  * Patients with a serum potassium ≤5.0mmol/L should be initiated on spironolactone or have the dose increased up to 100mg/day and randomised only if serum potassium exceeds 5.0mmol/L. Those intolerant of or unwilling to take spironolactone should be offered eplerenone titrated to a maximum dose of 50mg/day.~  * A run-in period of up to 35 days is permitted (the run-in period will usually occur during hospitalisation or a course of day-care or intense management).~2. After ingestion of a test-dose of patiromer,~   1. the patient is willing to continue in the trial~  2. the investigator considers the patient can follow instructions on preparing patiromer~      Exclusion criteria~      A, For the Screening Log \& Registry~      - None~      B. For the Randomised Trial~     1. eGFR \<30ml/minute/1.73m2 (if clinically appropriate, the dose of other agents such as loop diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers and sacubitril-valsartan may be adjusted to allow eGFR to increase)~     2. Systolic BP \<90mmHg~     3. Uncorrected valve disease as the main cause of heart failure in the investigators opinion~     4. Hepatic encephalopathy or known severe liver disease~     5. Infection currently requiring intravenous antibiotics or temperature \>38°C~     6. Myocardial ischaemia currently requiring intravenous therapy or coronary intervention in the previous 7 days~     7. Arrhythmia requiring urgent cardioversion or intravenous therapy~     8. Severe hyperkalaemia requiring, in the investigator's opinion, intravenous treatment or a potassium-binding agent~     9. The patient is already receiving a potassium-binding agent (this includes patiromer) or the treating physician has already decided to use one~     10. Known hypersensitivity to patiromer or any of the excipients~     11. Known intolerance to both spironolactone and eplerenone (not including hyperkalaemia)~     12. Known hypersensitivity to the active substance or excipients of spironolactone and eplerenone as per the current Summary of Product Characteristics (Note: actual medicine supplied to participants will vary depending on local arrangements)~     13. Women of childbearing potential. For the purposes of this trial this means any woman aged \<60 years unless they have had a hysterectomy or bilateral tubal ligation or are aged \>50 years and have undergone the menopause and had amenorrhea for at least 3 years~     14. Patients taking the following systemic medicines:~          * strong inhibitors of CYP 3A4 (e.g. itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone)~         * Lithium~         * Tacrolimus or Cyclosporin~     15. The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)~     16. Rare hereditary problems of galactose or fructose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption~     17. Known amyloid heart disease~     18. Cancer likely to cause death or major disability within the next three years~     19. Patients requiring mechanical circulatory support and~     20. Patients who do not develop a serum potassium \>5.0mmol/L despite receiving up to 100mg/day of spironolactone or 50mg/day of eplerenone during the run in phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose MRA (Type: NO_INTERVENTION): Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
- Patiromer and high dose MRA (Type: EXPERIMENTAL): Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues